Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored
Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored
Synairgen announces results of in vitro studies showing antiviral activity of interferon-beta against key SARS-CoV-2 variants
Preliminary results for the year ended 31 December 2020
Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
– SNG001 given Fast Track designation and IND cleared by the US FDA – Phase III trial design adapted which will expedite results – Phase III trial to commence dosing
Data from SG016 Phase II Clinical Trial published in Lancet Respiratory Medicine
Southampton, UK – 21 July 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company which originated from research at the University of Southampton, issues clarification with respect
Patients who received SNG001 had a 79% lower risk of developing severe disease compared to placebo Patients who received SNG001 were more than twice as likely to recover from COVID-19